U.S. Solid Tumor Testing Market - Analysis and Forecast, 2019-2030

Focus on Technology, Cancer Type, Biomarker Type, Application, End User, State Region, and Competitive Landscape

Published Year: 2020
SKU: BH00316SA

9000

Online Access for One Person. Permission to Print

A quick peek into the report

Report Description

U.S. solid tumor testing market is projected to reach $15,396.4 million by 2030 from $8,179.7 million in 2019, at a CAGR of 5.91%

Market Report Coverage - U.S. Solid Tumor Testing Market

 

 

Base Year

 

2019

 

Market Size by 2019

 

 $8.18 billion

 

Forecast Period

 

2020-2030

 

Value Estimation by 2030

 

 $15.396 billion

 

CAGR During Forecast Period

 

5.91%

 

Number of Tables

 

 

 

Number of Pages

 

 

 

 

Market Segmentation

 

• Technology – Next-Generation Sequencing, In Situ Hybridization, Polymerase Chain Reaction, Immunohistochemistry, and others

• Cancer Type – Breast cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, Melanoma, Endometrial Cancer, Thyroid Cancer, Brain Cancer, Ovarian Cancer, Liver Cancer, and others

• Type of Biomarker – Genetic Biomarkers, Protein Biomarkers, and others

• Application – Clinical and Research

• End-User – Hospitals, Diagnostic Laboratories & Reference Laboratories, Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic Research Institutions, and others

 

 

Regional Segmentation

 

The South U.S., Midwest U.S., Mid-Atlantic U.S. West U.S., Southwest U.S., and New England

 

Key Companies Profiled

 

Abbott Laboratories, Laboratory Corporation of America, Quest Diagnostics Incorporated, Illumina, F. Hoffmann-La Roche, ARUP Laboratories, Bio-Rad Laboratories Inc., Asuragen Inc., Cancer Genetics Inc., Invitae Corporation, NeoGenomics Laboratories, Inc., and QIAGEN N.V.

Market Outlook

Market Segmentation by Technology

Out of the wide array of products and services offered, the next-generation sequencing (NGS) segment accounts for the largest market volume. In 2019, the segment held an overall market share of 31.27% and is expected to maintain its dominance during 2019-2030. The polymerase chain reaction (PCR) technique is expected to continue its use as a confirmatory test for NGS-based assessments and is thus, anticipated to exhibit significant growth in the coming decade.

Market Segmentation by Cancer Type

Among the several types of solid tumors, the breast cancer segment occupied the largest market share, while covering 24.68% of the overall market size in 2019. The segment is expected to retain its dominance in the coming years due to the rising prevalence of breast cancer within the U.S. population. Owing to the criticality of this particular cancer type, the co-development of drug-diagnostic has been driven into focusing upon breast cancer, thereby ensuring more patients go through significant testing modules in the country.  

Market Segmentation by Biomarker Type

The genetic biomarkers market segment occupied more than half of the market share in 2019. During the forecast period, 2019-2030, the genetic biomarker segment is expected to grow to a share of 76.90% in 2030. As precision medicine initiatives continue to dominate the U.S. healthcare continuum, genomic databases are becoming a highly sensitive commodity for biotechnology and pharmaceutical companies for drug development purposes.

Market Segmentation by Application

The rising trend and adoption of solid tumor testing for clinical applications have escalated tremendously in the previous years. With the largest market share of 75.23% in 2019, clinical application sub-segment is expected to grow significantly in the coming years. However, research applications are also increasing significantly in the country, owing to the growth in funding initiatives being undertaken.

U.S. Solid tumer Testing Market

Market Segmentation by End User

Among the several end-users in the U.S. solid tumor testing market, the hospitals, diagnostic laboratories, and reference laboratories segment occupied the largest market share in 2019. As a result of growth in clinical applications, this end-user segment is expected to exhibit tremendous growth opportunities during the forecast period.

Market Segmentation by Region

Within the vast geography of the U.S., the state of California exhibited dominance in both market share and market growth. According to research by the American Cancer Society, California is estimated to have at least 172,040 new cancer cases in the year 2020. Furthermore, due to the presence of leading market players, such as Genoptix, Caris Life Sciences, and NeoGenomics Laboratories, the solid tumor testing market is expected to boom in the region.

Key Questions Answered in this Report

What is solid tumor testing? How have different testing technologies for solid tumor testing evolved over the centuries?

Key Questions Answered:

•    What is solid tumor testing? How have different testing technologies for solid tumor testing evolved over the centuries?
•    What are the major market drivers, challenges, and opportunities in the U.S. solid tumor testing market?
•    What was the U.S. solid tumor testing market size in terms of revenue in 2019? How is the market expected to evolve in the upcoming years? What is the expected market size in 2030?
•    How is each segment of the U.S. solid tumor testing market expected to grow during the forecast period between 2020 to 2030, and what is the revenue expected to be generated by each of the segments by the end of 2030?
•    What are the developmental strategies implemented by the key players to sustain in the competitive market?
•    What is the growth potential of the solid tumor testing market in several states across the U.S.?
•    Which product among the two (kits and services) are offered by key players such as Laboratory Corporation of America, Quest Diagnostics Incorporated, Abbott Laboratories, Illumina Inc., Qiagen N.V., and F. Hoffmann-La Roche Ltd.? 
•    Which technology was leading the market in 2019 and expected to dominate the market by 2030 and why?
•    Which application type was leading the market in 2019 and is expected to dominate the market in 2030 and why?
•    Which region dominated the U.S. solid tumor testing market in 2019, and what are the expected trends from each of the regions in the forecast period 2020-2030?

Market Overview

The term solid tumor refers to abnormal cellular growths, which generally comprise sarcomas, carcinomas, and lymphomas.

Market Overview and Estimation

According to the National Cancer Institute (NCI), a solid tumor is defined as “an abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumors may be benign (not cancer) or malignant (cancer).” Over recent years, the number of incidences for major solid tumors that include breast cancer, prostate cancer, colorectal cancer, lung cancer, and melanoma, among others, have escalated drastically.

In 2018, the overall economic burden of solid tumors on the U.S. reached approximately $144.15 billion, witnessing a growth of 21% from 2010. Among the American states, California, and Florida lead in terms of the estimated number of new cancer cases in 2020, with 172,040 and 150,500 new cases, respectively. Other states in the country, namely Illinois, Michigan, Pennsylvania, and Texas, are also emerging hotspots for the rising number of cancer cases in the country.

According to the market research conducted by BIS Research, the U.S. solid tumor testing market is projected to reach the mark of $15.396 billion by 2030, from a market value of $8.18 billion in 2019. With a CAGR of 5.91% during the forecast period 2020-2030, the market growth is attributed to several factors such as the rising incidence of cancer in the country, increasing adoption of inorganic growth strategies by key market players, and increasing research funding from the NCI.

Several market opportunities, such as the introduction of informatics and technological innovations for a large customer base and increasing adoption of genetic testing services, have boosted the market growth in the coming decade. Furthermore, the recent allocation of $6.44 billion to NCI in FY2020, as per the Department of Health and Human Services Appropriations Act and the 21st Century Cures Act, has brightened the prospects of key players to bring a diagnostic or therapeutic innovation in the market.

U.S. Solid tumer Testing Industry

 

Growth Drivers

 

• Rising Incidence of Cancers

• Decreasing Cost of Sequencing
• Increasing Adoption of Inorganic Growth Strategies in the Market

• Increasing Research Funding from National Cancer Institute

• Expected Increase in Adoption of Genetic Testing

 

 

Market Challenges

 

• Reimbursement Cuts in the U.S.

• Expected Implementation of Patient Protection and Affordable Care Act in the U.S.

• High Pricing Pressure

 

Market Opportunities

 

• Informatics and Technological Innovation for Larger Consumer Base

• Mushrooming Direct-to-Consumer (DTC) Testing Services Market
 

 

Growth Factors

Rising Incidence of Cancers

In 2017, the prevalence of breast cancer within the U.S. population was estimated to be 2,332,450.7, which is only expected to grow significantly over the next decade. The consistent evolution of technology increasing the sensitivity of cancer diagnosis, increased number of patients undergoing testing, and an overall approach toward precision medicine have created tremendous opportunities for solid tumor testing in the region.

Increasing Adoption of Inorganic Growth Strategies in the Market

Due to the ever-increasing incidence of cancer, several key market players are working to align their technologies as per the market demands to provide technologically advanced products and services by adopting inorganic strategies such as agreements, partnerships, and collaborations.

Increasing Research Funding from the National Cancer Institute

The National Cancer Institute (NCI) has launched two grants, namely, Small Business and Small Business Technology Transfer (SBIR & STTR) and Translational research grant for cancer prevention, diagnosis, and research. These grants create opportunities for the private sector and small businesses to participate in the research, development, and commercialization of novel technologies for cancer treatment.

Decreasing Cost of Sequencing

From 2010 to today, DNA sequencing has become faster and cheaper, and this progress can be attributed to the advances being developed and achieved in NGS technologies. Furthermore, due to the recent advancements, the utilization of NGS services has started to become a regular practice in clinical settings, with special emphasis on the technology’s use for cancer diagnosis and treatment planning.

Table of Contents

1 Product Definition

      1.1   Inclusion and Exclusion

2 Market Scope

      2.1   Scope of Work
      2.2   Key Questions Answered in the Report

3 Research Methodology

      3.1   U.S. Solid Tumors Testing Market: Research Methodology
      3.2   Data Sources
      3.3   Secondary Data Sources
      3.4   Market Estimation Model
      3.5   Criteria for Company Profiling

4 Market Overview

      4.1   Definition
      4.2   Solid Tumor Testing Technologies
      4.3   Market Size and Growth Potential, $Million, 2019-2030
      4.4   Industry Participants Landscape

5 Epidemiology of Solid Tumors in U.S.

      5.1   Epidemiology of Solid Tumors in U.S.

6 Industry Insights

      6.1   Regulation of Genetic Tests
              6.1.1   FDA Regulation
              6.1.2   CMS Regulation
      6.2   Reimbursement Scenario
              6.2.1 Impact on Laboratory Industry

7 Market Dynamics

      7.1   Market Drivers
              7.1.1   Rising Incidence of Cancers
              7.1.2   Decreasing Cost of Sequencing
              7.1.3   Increasing Adoption of Inorganic Growth Strategies in the Market
              7.1.4   Increasing Research Funding from National Cancer Institute
              7.1.5   Expected Increase in Adoption of Genetic Testing
      7.2   Restraints
              7.2.1   Reimbursement Cuts in the U.S.
              7.2.2   Expected Implementation of Patient Protection and Affordable Care Act in the U.S.
              7.2.3   High Pricing Pressure
      7.3   U.S. Market Opportunities
              7.3.1   Informatics and Technological Innovation for Larger Consumer Base
              7.3.2   Mushrooming Direct-to-Consumer (DTC) Testing Services Market

8 Competitive Landscape

      8.1   Key Strategies and Developments
              8.1.1   Synergistic Activities
              8.1.2   Approvals
              8.1.3   Product Launches, Enhancements and Expansion
              8.1.4   Acquisitions and Mergers
      8.2   Product Scenario
      8.3   Funding Scenario
      8.4   Market Share Analysis
      8.5   Growth Share Analysis (Opportunity Mapping)
              8.5.1   By Company
              8.5.2   By Technology
              8.5.3   By Application
              8.5.4   By Cancer Type

9 U.S. Solid Tumor Testing Market (by Technology)

      9.1   Overview
      9.2   Next-Generation Sequencing
      9.3   In Situ Hybridization
      9.4   Polymerase Chain Reaction
      9.5   Immunohistochemistry
      9.6   Other Technologies

10 U.S. Solid Tumor Testing Market (by Cancer Type)

        10.1   Overview
        10.2   Breast Cancer
        10.3   Prostate Cancer
        10.4   Colorectal Cancer
        10.5   Lung Cancer
        10.6   Melanoma
        10.7   Endometrial Cancer
        10.8   Thyroid Cancer
        10.9   Brain Cancer
        10.10   Ovarian Cancer
        10.11   Liver Cancer
        10.12   Other Cancer Types

11 U.S. Solid Tumor Testing Market (by Type of Biomarker)

        11.1   Overview
        11.2   Genetic Biomarkers
        11.3   Protein Biomarkers
        11.4   Other Biomarkers

12 U.S. Solid Tumor Testing Market (by Application)

        12.1   Overview
        12.2   Clinical
        12.3   Research

13 U.S. Solid Tumor Testing Market (by End User)

        13.1   Overview
        13.2   Hospitals, Diagnostic Laboratories, and Reference Laboratories
        13.3   Pharmaceutical and Biotechnology Companies
        13.4   Contract Research Organizations
        13.5   Academic Research Institutions
        13.6   Other End Users

14 U.S. Solid Tumor Testing Market (by State Region)

        14.1   Overview
        14.2   The South U.S.
        14.3   The Midwest U.S.
        14.4   The Mid-Atlantic U.S.
        14.5   The West U.S.
        14.6   The Southwest U.S.
        14.7   New England

15 Company Profiles

        15.1   Overview
        15.2   Abbott Laboratories
                  15.2.1   Company Overview
                  15.2.2   Role of Abbott Laboratories in the U.S. Solid Tumor Testing Market
                  15.2.3   Financials
                  15.2.4   Key Insights About Financial Health of the Company
                  15.2.5   SWOT Analysis
        15.3   Illumina, Inc.
                  15.3.1   Company Overview
                  15.3.2   Role of Illumina, Inc. in the U.S. Solid Tumor Testing Market
                  15.3.3   Financials
                  15.3.4   Key Insights About Financial Health of the Company
                  15.3.5   SWOT Analysis
         15.4   F. Hoffmann-La Roche Ltd.
                  15.4.1   Company Overview
                  15.4.2   Role of F. Hoffmann-La Roche Ltd in the U.S. Solid Tumor Testing Market
                  15.4.3   Financials
                  15.4.4   Key Insights About Financial Health of the Company
                  15.4.5   SWOT Analysis
        15.5   Bio-Rad Laboratories, Inc.
                  15.5.1   Company Overview
                  15.5.2   Role of Bio-Rad Laboratories, Inc. in the U.S. Solid Tumor Testing Market
                  15.5.3   Financials
                  15.5.4   Key Insights About Financial Health of the Company
                  15.5.5   SWOT Analysis
        15.6   ASURAGEN, INC.
                  15.6.1   Company Overview
                  15.6.2   Role of ASURAGEN, INC. in the U.S. Solid Tumor Testing Market
                  15.6.3   SWOT Analysis
        15.7   Cancer Genetics Inc.
                  15.7.1   Company Overview
                  15.7.2   Role of Cancer Genetics Inc.in the U.S. Solid Tumor Testing Market
                  15.7.3   Financials
                  15.7.4   Key Insights About Financial Health of the Company
                  15.7.5   SWOT Analysis
        15.8   QIAGEN N.V.*
                  15.8.1   Company Overview
                  15.8.2   Role of QIAGEN N.V. in the U.S. Solid Tumor Testing Market
                  15.8.3   Financials
                  15.8.4   Key Insights about Financial Health of the Company
                  15.8.5   SWOT Analysis
        15.9   Quest Diagnostics Incorporated
                  15.9.1   Company Overview
                  15.9.2   Role of Quest Diagnostics Limited in the U.S. Solid Tumor Testing Market
                  15.9.3   Financials
                  15.9.4   SWOT Analysis
      15.10   ARUP Laboratories
                  15.10.1   Company Overview
                  15.10.2   Role of ARUP Laboratories in the U.S. Solid Tumor Testing Market
                  15.10.3   SWOT Analysis
       15.11   Invivoscribe, Inc.
                  15.11.1   Company Overview
                  15.11.2   Role of Invivoscribe, Inc. in the U.S. Solid Tumor Testing Market
                  15.11.3   SWOT Analysis
      15.12   NeoGenomics Laboratories, Inc.
                  15.12.1   Company Overview
                  15.12.2   Role of NeoGenomics Laboratories, Inc. in the U.S. Solid Tumor Testing Market
                  15.12.3   Financials
                  15.12.4   Key Insights About Financial Health of the Company
                  15.12.5   SWOT Analysis
       15.13   Invitae Corporation
                  15.13.1   Company Overview
                  15.13.2   Role of Invitae Corporation, Inc. in the U.S. Solid Tumor testing Market
                  15.13.3   Financials
                  15.13.4   Key Insights About Financial Health of the Company
                  15.13.5   SWOT Analysis
      15.14   Opko Health
                  15.14.1   Company Overview
                  15.14.2   Role of Opko Health, Inc. in the U.S. Solid Tumor Testing Market
                  15.14.3   Financials
                  15.14.4   Key Insights About Financial Health of the Company
                  15.14.5   SWOT Analysis
       15.15   Laboratory Corporation of America Holdings
                  15.15.1   Company Overview
                  15.15.2   Role of Laboratory Corporation of America Holdings in the U.S. Solid Tumor Testing Market
                  15.15.3   Financials
                  15.15.4   SWOT Analysis
      15.16   OmniSeq
                  15.16.1   Company Overview
                  15.16.2   Role of OmniSeq in the U.S. Solid Tumor Testing Market
                  15.16.3   SWOT Analysis
      15.17   Nanostring Technologies
                  15.17.1   Company Overview
                  15.17.2   Role of Nanostring Technologies in the U.S. Solid Tumor Testing Market
                  15.17.3   Financials
                  15.17.4   SWOT Analysis
      15.18   Guardant Health
                  15.18.1   Company Overview
                  15.18.2   Role of Guardant Health in the U.S. Solid Tumor Testing Market
                  15.18.3   Financials
                  15.18.4   SWOT Analysis
      15.19   Personal Genome Diagnostics
                  15.19.1   Company Overview
                  15.19.2   Role of Personal Genome Diagnostics in the U.S. Solid Tumor Testing Market
                  15.19.3   SWOT Analysis
      15.20   HTG Molecular Diagnostics
                  15.20.1   Company Overview
                  15.20.2   Role of HTG Molecular Diagnostics in the U.S. Solid Tumor Testing Market
                  15.20.3   Financials
                  15.20.4   SWOT Analysis
      15.21   Caris Life Sciences
                  15.21.1   Company Overview
                  15.21.2   Role Caris Life Sciences in the U.S Solid Tumor Testing Market
                  15.21.3   SWOT Analysis
      15.22   Genomic Testing Cooperative
                  15.22.1   Company Overview
                  15.22.2   Role of Genome Testing Cooperative in the U.S Solid Tumor Testing Market
                  15.22.3   SWOT Analysis
      15.23   ArcherDX, Inc.
                  15.23.1   Company Overview
                  15.23.2   Role of ArcherDX, Inc. in the U.S Solid Tumor Testing Market
                  15.23.3   SWOT Analysis

List of Tables

Table 4.1:    Solid Tumor Testing Technologies for Clinical Laboratories
Table 4.2:    Technological Trends in Solid Tumor Testing Market
Table 4.3:    Industry Participants Landscape in the U.S Solid Tumor Testing Market
Table 6.1:    Examples of New CPT Codes Under the CMS
Table 6.2:    New Payment Amounts for ADLTs
Table 7.1:    Consolidated Variations in Medicaid & Medicare Revenues Reported by U.S. Majors as Per PAMA
Table 8.1:    Market Players With Key Product Listing
Table 8.2:    Cancer Moonshot Initiative Partners
Table 11.1:    FDA-Approved Stratification Biomarkers for Targeted Therapy in Oncology

List of Figures

Figure 1:    NCI Fiscal Budget Year on Year, 2013-2018
Figure 2:    Impact Analysis of Market Drivers and Market Challenges on the U.S. Solid Tumor Testing Market
Figure 3:    U.S. Solid Tumor Testing Market (by Technology), $Million, 2019 and 2030
Figure 4:    U.S. Solid Tumor Testing Market (by Cancer Type), $Million, 2019 and 2030
Figure 5:    U.S. Solid Tumor Testing Market (by Biomarker Type), $Million, 2019 and 2030
Figure 6:    U.S. Solid Tumor Testing Market (by Application), $Million, 2019 and 2030
Figure 7:    U.S. Solid Tumor Testing Market (by End User), $Million, 2019 and 2030
Figure 8:    Top 5 Contributing States to the U.S. Solid Tumor Testing Market
Figure 2.1:    U.S. Solid Tumor Testing Market Segmentation
Figure 3.1:    U.S. Solid Tumor Testing Market Research Methodology
Figure 3.2:    Primary Research Methodology
Figure 3.3:    Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4:    Top-Down Approach (Segment-Wise Analysis)
Figure 4.1:    U.S. Solid Tumor Testing Market 2019-2030
Figure 5.1:    Type of Solid Tumors
Figure 5.2:    Estimated Percent of New Cancer Cases (by Sex), United States, 2020
Figure 5.3:    Expected Cancers Cases in the U.S. (by State), 2020
Figure 5.4:    Relative Number of Expected Cancers Cases (by State), 2020
Figure 5.5:    Relative Percent of Expected Cancers Cases (by Region), 2020
Figure 5.6:    Prevalence of Different Cancers Across the U.S. (2013-2017) *
Figure 7.1:    Market Dynamics of U.S. Solid Tumor Testing Market
Figure 7.2:    Cancer Cases Projections, 2015-2020
Figure 7.3:    Decreasing Cost and Increasing Output (TB) of Genome Sequencing  (2009-2025)
Figure 7.4:    Synergistic Activities, 2017-2019
Figure 7.5:    SBIR and STTR Grants and Contract Funding, 2008-2018
Figure 7.6:    NCI Fiscal Budget Year on Year, 2013-2018
Figure 7.7:    Reimbursement Cuts Adopted for Oncology Testing, as per PAMA Revisions
Figure 8.1:    Share of Key Developments and Strategies, January 2017-December 2019
Figure 8.2:    Synergistic Activities Share (by Company), January 2017-December 2019
Figure 8.3:    Approvals Share (by Company), January 2017-December 2019
Figure 8.4:    Product Launches and Expansion Share (by Company), January 2017-December 2019
Figure 8.5:    Acquisitions and Mergers Share (by Company), January 2017-December 2019
Figure 8.6:    NCI Budget Allocation, FY2015-FY2018
Figure 8.7:    Fund Allocation for Cancer Moonshot Program
Figure 8.8:    Market Share Analysis for the U.S. Solid Tumor Testing Market, 2019
Figure 8.9:    Growth Share Matrix for U.S. Solid Tumor Testing Market (by Company), 2019
Figure 8.10:    Growth Share Matrix for U.S. Solid Tumor Testing Market (by Technology), 2019
Figure 8.11:    Growth Share Matrix for U.S. Solid Tumor Testing Market (by Application), 2019
Figure 8.12:    Growth Share Matrix for U.S Solid Tumor Testing Market (by Cancer Type), 2019
Figure 9.1:    U.S. Solid Tumor Testing Market (by Technology), 2019-2030
Figure 9.2:    U.S. Solid Tumor Testing Market (for NGS), 2019-2030
Figure 9.3:    U.S. Solid Tumor Testing Market (for Type of NGS Sequencing), 2019-2030
Figure 9.4:    U.S. Solid Tumor Testing Market (for ISH), 2019-2030
Figure 9.5:    U.S. Solid Tumor Testing Market (for PCR), 2019-2030
Figure 9.6:    U.S. Solid Tumor Testing Market (for IHC), 2019-2030
Figure 9.7:    U.S. Solid Tumor Testing Market (for Other Technologies), 2019-2030
Figure 10.1:    Economic Burden of Major Cancer Types on the U.S. Economy, 2010-2018
Figure 10.2:    U.S. Solid Tumor Testing Market (by Cancer Type), 2019-2030
Figure 10.3:    Prevalence of Breast Cancer in U.S., 2013-2017
Figure 10.4:    U.S. Solid Tumor Testing Market (for Breast Cancer), 2019-2030
Figure 10.5:    Total Market Size for U.S. Solid Tumor Testing Market (for Breast Cancer, by Technology), 2019 and 2030
Figure 10.6:    Prevalence of Prostate Cancer in U.S., 2013-2017
Figure 10.7:    U.S. Solid Tumor Testing Market (for Prostate Cancer), 2019-2030
Figure 10.8:    Total Market Size for U.S. Solid Tumor Testing Market (for Prostate Cancer, by Technology), 2019 and 2030
Figure 10.9:    Prevalence of Colorectal Cancer in U.S., 2013-2017
Figure 10.10:    U.S. Solid Tumor Testing Market (for Colorectal Cancer), 2019-2030
Figure 10.11:    Total Market Size for U.S. Solid Tumor Testing Market (for Colorectal Cancer, by Technology), 2019 and 2030
Figure 10.12:    Prevalence of Lung Cancer in U.S., 2013-2017
Figure 10.13:    U.S. Solid Tumor Testing Market (for Lung Cancer), 2019-2030
Figure 10.14:    Total Market Size for U.S. Solid Tumor Testing Market (for Lung Cancer, by Technology), 2019 and 2030
Figure 10.15:    Prevalence of Melanoma in U.S., 2013-2017
Figure 10.16:    U.S. Solid Tumor Testing Market (for Melanoma), 2019-2030
Figure 10.17:    Total Market Size for U.S. Solid Tumor Testing Market (for Melanoma, by Technology), 2019 and 2030
Figure 10.18:    Prevalence of Endometrial Cancer in U.S., 2013-2017
Figure 10.19:    U.S. Solid Tumor Testing Market (for Endometrial Cancer), 2019-2030
Figure 10.20:    Total Market Size for U.S. Solid Tumor Testing Market (for Endometrial Cancer, by Technology), 2019 and 2030
Figure 10.21:    Prevalence of Thyroid Cancer in U.S., 2013-2017
Figure 10.22:    U.S. Solid Tumor Testing Market (for Thyroid Cancer), 2019-2030
Figure 10.23:    Total Market Size for U.S. Solid Tumor Testing Market (for Thyroid Cancer, by Technology), 2019 and 2030
Figure 10.24:    Prevalence of Brain Cancer in U.S., 2013-2017
Figure 10.25:    U.S. Solid Tumor Testing Market (for Brain Cancer), 2019-2030
Figure 10.26:    Total Market Size for U.S. Solid Tumor Testing Market (for Brain Cancer, by Technology), 2019 and 2030
Figure 10.27:    Prevalence of Ovarian Cancer in U.S., 2013-2017
Figure 10.28:    U.S. Solid Tumor Testing Market (for Ovarian Cancer), 2019-2030
Figure 10.29:    Total Market Size for U.S. Solid Tumor Testing Market (for Ovarian Cancer, by Technology), 2019 and 2030
Figure 10.30:    Prevalence of Liver Cancer in U.S., 2013-2017
Figure 10.31:    U.S. Solid Tumor Testing Market (for Liver Cancer), 2019-2030
Figure 10.32:    Total Market Size for U.S. Solid Tumor Testing Market (for Liver Cancer, by Technology), 2019 and 2030
Figure 10.33:    U.S. Solid Tumor Testing Market (for Other Cancer Types), 2019-2030
Figure 10.34:    Total Market Size for U.S. Solid Tumor Testing Market (for Other Cancer Types, by Technology), 2019 and 2030
Figure 11.1:    U.S. Solid Tumor Testing Market (by Type of Biomarker), 2019-2030
Figure 11.2:    Technologies and Data Types for Genetic Biomarker Discovery
Figure 11.3:    U.S. Solid Tumor Testing Market (for Genetic Biomarkers), 2019-2030
Figure 11.4:    Technologies and Data Types for Protein Biomarker Discovery
Figure 11.5:    U.S. Solid Tumor Testing Market (for Protein Biomarkers), 2019-2030
Figure 11.6:    U.S. Solid Tumor Testing Market (for Other Biomarkers), 2019-2030
Figure 12.1:    U.S. Solid Tumor Testing Market (by Application), 2019-2030
Figure 12.2:    U.S. Solid Tumor Testing Market (for Clinical Applications), 2019-2030
Figure 12.3:    U.S. Solid Tumor Testing Market (for Types of Clinical Applications),  2019-2030
Figure 12.4:    U.S. Solid Tumor Testing Market (for Research Applications), 2019-2030
Figure 12.5:    U.S. Solid Tumor Testing Market (for Types of Research Applications),  2019-2030
Figure 13.1:    U.S. Solid Tumor Testing Market (by End User), 2019-2030
Figure 13.2:    U.S. Solid Tumor Testing Market (for Hospitals, Diagnostic Laboratories, and Reference Laboratories), 2019-2030
Figure 13.3:    U.S. Solid Tumor Testing Market (for Pharmaceutical and Biotechnology Companies), 2019-2030
Figure 13.4:    U.S. Solid Tumor Testing Market (for Contract Research Organization), 2019-2030
Figure 13.5:    U.S. Solid Tumor Testing Market (for Academic Research Institutions), 2019-2030
Figure 13.6:    U.S. Solid Tumor Testing Market (for Other End Users), 2019-2030
Figure 14.1:    U.S. Solid Tumor Testing Market (by State Region), 2019-2030
Figure 14.2:    Growth in Top 5 States in the U.S. Solid Tumor Testing Market, 2019-2030
Figure 14.3:    The South U.S. Solid Tumor Testing Market, 2019-2030
Figure 14.4:    The South U.S. Solid Tumor Testing Market (by State), 2019, 2025, and 2030
Figure 14.5:    The Midwest U.S. Solid Tumor Testing Market, 2019-2030
Figure 14.6:    The Midwest U.S. Solid Tumor Testing Market (by State), 2019, 2025, and 2030
Figure 14.7:    The Mid-Atlantic U.S. Solid Tumor Testing Market, 2019-2030
Figure 14.8:    The Mid-Atlantic U.S. Solid Tumor Testing Market (by State), 2019, 2025, and 2030
Figure 14.9:    The West U.S. Solid Tumor Testing Market, 2019-2030
Figure 14.10:    The West U.S. Solid Tumor Testing Market (by State), 2019, 2025, and 2030
Figure 14.11:    The Southwest U.S. Solid Tumor Testing Market, 2019-2030
Figure 14.12:    The Southwest U.S. Solid Tumor Testing Market (by State), 2019, 2025, and 2030
Figure 14.13:    New England Solid Tumor Testing Market, 2019-2030
Figure 15.1:    Total Number of Companies Profiled
Figure 15.2:    Abbott Laboratories: Portfolio
Figure 15.3:    Abbott Laboratories: Overall Financials, 2017-2019
Figure 15.4:    Abbott Laboratories: Revenue (by Segment), 2017-2019
Figure 15.5:    Abbott Laboratories: Revenue Split for Diagnostics, 2017-2019
Figure 15.6:    Abbott Laboratories: Revenue (by Region), 2017-2019
Figure 15.7:    Abbott Laboratories: R&D Expenditure, 2017-2019
Figure 15.8:    Abbott Laboratories: SWOT Analysis
Figure 15.9:    Illumina, Inc.: Portfolio
Figure 15.10:    Illumina, Inc.: Overall Financials, 2017-2019
Figure 15.11:    Illumina, Inc.: Revenue (by Segment), 2017-2019
Figure 15.12:    Illumina, Inc.: Revenue (by Region), 2017-2019
Figure 15.13:    Illumina, Inc.: R&D Expenditure, 2017-2019
Figure 15.14:    Illumina, Inc.: SWOT Analysis
Figure 15.15:    F. Hoffmann-La Roche Ltd: Portfolio
Figure 15.16:    F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
Figure 15.17:    F. Hoffmann-La Roche Ltd: Sales (by Segment), 2017-2019
Figure 15.18:    F. Hoffmann-La Roche Ltd: Sales (by Region), 2017-2019
Figure 15.19:    F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
Figure 15.20:    F. Hoffmann-La Roche: SWOT Analysis
Figure 15.21:    Bio-Rad Laboratories, Inc.: Portfolio
Figure 15.22:    Bio-Rad Laboratories, Inc.: Overall Financials, 2017-2019
Figure 15.23:    Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2017-2019
Figure 15.24:    Bio-Rad Laboratories, Inc.: Revenue (by Region), 2017-2019
Figure 15.25:    Bio-Rad Laboratories, Inc.: R&D Expenditure, 2017-2019
Figure 15.26:    Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 15.27:    ASURAGEN, INC.: Portfolio
Figure 15.28:    ASURAGEN, INC.: SWOT Analysis
Figure 15.29:    Cancer Genetics Inc.: Portfolio
Figure 15.30:    Cancer Genetics Inc.: Overall Financials, 2016-2018
Figure 15.31:    Cancer Genetics Inc.: Sales (by Segment), 2016-2018
Figure 15.32:    Cancer Genetics Inc.: Sales (by Region), 2016-2018
Figure 15.33:    Cancer Genetics Inc.: R&D Expenditure, 2016-2018
Figure 15.34:    Cancer Genetics Inc.: SWOT Analysis
Figure 15.35:    QIAGEN N.V.: Portfolio
Figure 15.36:    QIAGEN N.V.: Overall Financials, 2017-2019
Figure 15.37:    QIAGEN N.V.: Revenue (by Segment), 2017-2019
Figure 15.38:    QIAGEN N.V.: Revenue (by Region), 2017-2019
Figure 15.39:    QIAGEN N.V.: R&D Expenditure, 2017-2019
Figure 15.40:    QIAGEN N.V.: SWOT Analysis
Figure 15.41:    Quest Diagnostics Incorporated: Portfolio
Figure 15.42:    Quest Diagnostics Incorporated: Overall Financials, 2017-2019
Figure 15.43:    Quest Diagnostics Incorporated: Revenue (by Business Segment),  2017-2019
Figure 15.44:    Quest Diagnostics Incorporated: SWOT Analysis
Figure 15.45:    ARUP Laboratories: Portfolio
Figure 15.46:    ARUP Laboratories: SWOT Analysis
Figure 15.47:    Invivoscribe, Inc.: Portfolio
Figure 15.48:    Invivoscribe, Inc.: SWOT Analysis
Figure 15.49:    NeoGenomics Laboratories, Inc.: Portfolio
Figure 15.50:    NeoGenomics Laboratories, Inc.: Overall Financials, 2017-2019
Figure 15.51:    NeoGenomics Laboratories, Inc.: Revenue (by Segment), 2017-2019
Figure 15.52:    NeoGenomics Laboratories, Inc.: R&D Expenditure, 2017-2019
Figure 15.53:    NeoGenomics Laboratories, Inc.: SWOT Analysis
Figure 15.54:    Invitae Corporation: Portfolio
Figure 15.55:    Invitae Corporation: Overall Financials, 2017-2019
Figure 15.56:    Invitae Corporation: Revenue (by Segment), 2017-2019
Figure 15.57:    Invitae Corporation: Revenue (by Geography), 2017-2019
Figure 15.58:    Invitae Corporation: R&D Expenditure, 2017-2019
Figure 15.59:    Invitae Corporation: SWOT Analysis
Figure 15.60:    Opko Health: Portfolio
Figure 15.61:    Opko Health: Overall Financials, 2017-2019
Figure 15.62:    Opko Health: Revenue (by Segment), 2017-2019
Figure 15.63:    Opko Health: Revenue (by Region), 2017-2019
Figure 15.64:    Opko Health: R&D Expenditure, 2017-2019
Figure 15.65:    Opko Health: SWOT Analysis
Figure 15.66:    Laboratory Corporation of America Holdings: Portfolio
Figure 15.67:    Laboratory Corporation of America Holdings: Overall Financials, 2017-2019
Figure 15.68:    Laboratory Corporation of America Holdings: Revenue (by Segment), 2017-2019
Figure 15.69:    Laboratory Corporation of America Holdings: Revenue (by Region), 2019
Figure 15.70:    Laboratory Corporation of America Holdings: SWOT Analysis
Figure 15.71:    OmniSeq: Portfolio
Figure 15.72:    OmniSeq: SWOT Analysis
Figure 15.73:    Nanostring Technologies: Portfolio
Figure 15.74:    Nanostring Technologies: Overall Financials, 2017-2019
Figure 15.75:    Nanostring Technologies: Revenue (by Segment), 2017-2019
Figure 15.76:    Nanostring Technologies: Revenue (by Region), 2017-2019
Figure 15.77:    Nanostring Technologies: SWOT Analysis
Figure 15.78:    Guardant Health: Portfolio
Figure 15.79:    Guardant Health: Overall Financials, 2017-2019
Figure 15.80:    Guardant Health: Revenue (by Segment), 2017-2019
Figure 15.81:    Guardant Health: Revenue (by Region), 2017-2019
Figure 15.82:    Guardant Health: SWOT Analysis
Figure 15.83:    Personal Genome Diagnostics: Portfolio
Figure 15.84:    Personal Genome Diagnostics: SWOT Analysis
Figure 15.85:    HTG Molecular Diagnostics: Portfolio
Figure 15.86:    HTG Molecular Diagnostics: Overall Financials, 2017-2019
Figure 15.87:    HTG Molecular Diagnostics: Revenue (by Segment), 2017-2019
Figure 15.88:    HTG Molecular Diagnostics: SWOT Analysis
Figure 15.89:    Caris Life Sciences: Portfolio
Figure 15.90:    Caris Life Sciences: SWOT Analysis
Figure 15.91:    Genomic Testing Cooperative: Portfolio
Figure 15.92:    Genomic Testing Cooperative: SWOT Analysis
Figure 15.93:    ArcherDX, Inc.: Portfolio
Figure 15.94:    ArcherDX, Inc.: SWOT Analysis

You may also like

Published Year: 2019

Global Hematologic Malignancies Testing Market: Focus on Product, Disease, Technology, End User, Region/Country Data and Competitive Landscape – Analysis and Forecast, 2018-2025

The hematologic malignancies testing industry analysis by BIS Research projects the market to...

 
Published Year: 2019

Global Molecular Diagnostics Market: Focus on Product Type (Kits and Consumables, Systems, Software & Others), Applications, Technologies, End-User, Country Data (15 Countries), and Competitive Landscape, Analysis and Forecast, 2018-2028

The global molecular diagnostics market has been witnessing a steady growth since the end of...

 
Published Year: 2017

Global IVD(In-Vitro Diagnostics) Market - Analysis and Forecast 2017-2023: (Focus on Product Type, Test Type, Application, and Competitive Landscape)

IVD is expected to increase to $76 billion by 2023 and increase its influence over healthcare...

 

U.S. Solid Tumor Testing Market - Analysis and Forecast, 2019-2030

Focus on Technology, Cancer Type, Biomarker Type, Application, End User, State Region, and Competitive Landscape